Metropolis Healthcare Ltd. saw a year-on-year 23% uptick in revenue growth for the quarter ended June 30, according to an exchange filing on Friday.
Post-acquisition, Core Diagnostics has moved from breakeven position in Q4FY25 to a single-digit positive-margin trajectory. The firm's Ebitda margin is slightly lower because of Core's figures are included in the overall results, according to the filing.
Specialty revenues saw a growth up to 35% on a YoY basis due to the consolidation of Core which is largely high-end specialized oncology testing.
Q1FY26 Highlights, Excluding Acquisition Of Core, DAPIC And Scientific
Revenues grew approximately 13% YoY due to an increase in patient and test volumes. Business-to-consumer revenues were up 15% YoY.
The TruHealth Wellness and Specialty segments recorded a YoY growth of approximately 20% and 15%, respectively, in Q1FY26.
Earnings before interest taxes and depreciation for the June quarter improved on a quarter-on-quarter basis due to increased throughput, operational efficiencies and operating leverage and remained in line with the same period last year.
The company stated that it is debt free.
Shares of Metropolis Healthcare closed 2.04% higher at Rs 1,773.30 apiece on the NSE, compared to a 0.22% rise in the benchmark Nifty. The stock has fallen 15.01% in the last 12 months and 14.61% on a year-to-date basis.
Out of 24 analysts tracking the company, 18 have a 'buy' rating on the stock, two recommend 'hold' and four suggest 'sell', according to Bloomberg data. The average of 12-month analysts' price target implies a potential upside of 8.9%.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
